Pharsight

Dalvance patents expiration

DALVANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(a month from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(a month from now)

US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(a month from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections
May, 2028

(4 years from now)

Dalvance is owned by Allergan.

Dalvance contains Dalbavancin Hydrochloride.

Dalvance has a total of 4 drug patents out of which 0 drug patents have expired.

Dalvance was authorised for market use on 23 May, 2014.

Dalvance is available in powder;intravenous dosage forms.

Dalvance can be used as treatment of bacterial infections using a two-dose regimen of dalbavancin..

Drug patent challenges can be filed against Dalvance from 2023-05-24.

The generics of Dalvance are possible to be released after 23 May, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2019
New Patient Population (NPP) Jul 22, 2024
Generating Antibiotic Incentives Now (GAIN) May 23, 2024

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: 2023-05-24

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DALVANCE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic